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Achondroplasia	   is	   a	   short-­‐limbed	   dwarfism	   resulting	   from	   mutation	   and	   gain-­‐of-­‐
function	   in	   fibroblast	   growth	   factor	   receptor	   3	   (FGFR3).	   Effective	   therapy	   for	   this	  
condition	  has	  not	  as	   yet	  been	  established.	  We	  have	   tested	   the	  efficiency	  of	   three	  
different	   small	   interference	   RNAs	   (siRNAs)	   to	   abrogate	   the	   FGFR3	   expression	   in	  
human	   immortalized	   chondrocytes	   carrying	   the	   achondroplasia	  mutation	   (G380R).	  
Two	   siRNA	   sequences	   induced	   markedly	   decrease	   of	   FGFR3	   mRNA	   (up	   to	   75%	  
reduction)	   and	  protein	   levels	   (up	   to	   61%	   reduction).	   Furthemore,	   siRNA-­‐mediated	  
knockdown	  of	  FGFR3	  blocked	  the	  activation	  of	  the	  downstream	  signal	  transduction	  
ERK	  pathway.	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RESUMEN 
Inhibición	  del	  receptor	  FGFR3	  por	  ARNs	  de	  interferencia	  para	  la	  acondroplasia	  
La	   acondroplasia	   es	   un	   tipo	   de	   enanismo	   caracterizado	   por	   extremidades	   cortas	  
resultante	  de	  una	  mutación	  en	  el	  receptor	  de	  crecimiento	  de	  fibroblastos	  de	  tipo	  3	  
(FGFR3).	   Aún	   no	   se	   ha	   establecido	   una	   terapia	   efectiva	   para	   esta	   enfermedad.	  
Nosotros	   hemos	   testado	   la	   eficiencia	   de	   tres	   diferentes	   small	   interference	   RNAs	  
(siRNAs)	   para	   bloquear	   la	   expresión	   del	   receptor	   FGFR3	   en	   condrocitos	   humanos	  
inmortalizados	  portadores	  de	   la	  mutación	  acondroplásica	   (G380R).	  Dos	   secuencias	  
de	   siRNAs	   indujeron	  un	  marcado	  descenso	  de	   la	  expresión	  de	  ARN	  mensajero	  del	  
receptor	  FGFR3	  (hasta	  un	  75%)	  así	  como	  de	  los	  niveles	  de	  proteína	  (hasta	  un	  61%).	  
Además,	   el	   bloqueo	   de	   la	   expresión	   del	   receptor	   FGFR3	  mediado	   por	   los	   siRNAs	  
redujo	  la	  activación	  de	  la	  cascada	  de	  transducción	  de	  las	  ERK.	  
Palabras	   clave:	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1. INTRODUCTION Achondroplasia	   is	   the	   most	   common	   form	   of	   dwarfism	   in	   humans.	   This	  disorder	   is	   characterized	   by	   a	  mutation	   in	   the	   gene	   that	   encodes	   for	   the	   FGFR3	  receptor,	   being	   the	   mutation	   in	   97%	   of	   the	   patients	   a	   Glycine	   to	   Arginine	  substitution	  at	  position	  380.	  FGFR3	  is	  a	  regulator	  of	  endochondral	  bone	  growth	  and	  its	  mutation	  causes	  gain	   of	   function	   disturbing	   chondrocyte	   proliferation	   and	   differentiation	   during	  endochondral	   ossification	   process.	   As	   a	   result,	   the	   rate	   of	   cartilage	   template	  formation	  and	  turnover	  required	  for	  bone	  elongation	  are	  dramatically	  reduced	  (1).	  At	   the	   molecular	   level,	   sustained	   activation	   of	   mutant	   FGFR3	   stimulates	  several	   intracellular	   signalling	   pathways,	   including	   extracellular	   signal-­‐regulated	  kinases	   1	   and	   2	   (ERK1/2)	   cascade	   and	   signal	   transducer	   and	   activators	   of	  transcription	   (STAT-­‐1)	   pathway,	   that	   account	   for	   the	   critical	   changes	   in	  chondrocyte	   proliferation	   (2,	   3),	   differentiation	   (4)	   and	   extracellular	   matrix	  homeostasis	  (5).	  Potential	   therapeutic	   approaches	   have	   been	   proposed	   for	   achondroplasia	  treatment.	  The	  main	   strategies	   are	  based	  on	  blocking	  FGFR3	  activation	   (6,	   7)	   or	  interfering	   with	   the	   pathways	   that	   modulate	   the	   downstream	   propagation	   of	  FGFR3	  signals	   (5,	  8).	  However,	  despite	   the	  efforts,	   achondroplasia	   remains	  as	  an	  orphan	  pathology	  with	  no	  pharmacological	  treatment	  so	  far.	  RNA	   interference	   is	   a	   posttranscriptional	   process	   triggered	   by	   the	  introduction	  of	  double-­‐stranded	  RNA,	  which	  leads	  to	  gene	  silencing	  in	  a	  sequence-­‐specific	   manner.	   This	   is	   one	   of	   the	   most	   exciting	   new	   findings	   in	   functional	  genomics	   of	   the	   past	   decade	   and	   its	   potential	   for	   experimental	   and	   therapeutic	  purposes	  is	  currently	  under	  investigation	  (9).	  In	   this	   work,	   we	   transfected	   immortalized	   human	   chondrocytes	   carrying	  the	   heterozygous	   achondroplasia	   mutation	   (G380R)	   with	   three	   different	   small	  interfering	   RNAs	   (siRNAs)	   and	   analyzed	   their	   effect	   on	   FGFR3	   expression	   and	  prolonged	   signalling	   to	   evaluate	   the	   therapeutical	   potential	   of	   siRNAs	   in	  achondroplasia	  treatment.	  
 
2. MATERIALS AND METHODS 
2.1.	  Cells	  Immortalized	   human	   chondrocytes	   carrying	   the	   heterozygous	  achondroplasia	   mutation	   (G380R)	   were	   generated	   and	   characterized	   by	   Dr.	  Laurence	   Legeai-­‐Mallet	   (10).	   Cells	   were	   cultured	   in	   Dulbecco´s	  modified	   Eagle´s	  medium	   (Invitrogen,	   Paisley,	   UK)	   supplemented	   with	   10%	   fetal	   calf	   serum,	   1%	  penicillin/streptomicyn	   and	   500	   ng/ml	   geneticin	   (all	   obtained	   from	   Invitrogen)	  and	  were	  incubated	  at	  37	  ºC	  with	  5%	  CO2.	  
2.2.	  Small	  interfering	  RNA	  design	  and	  Transfection	  Using	  siRNA	  design	  software,	   three	  siRNA	  duplexes	   targeting	  FGFR3	  were	  obtained	   from	   Ambion	   (Applied	   Biosystems,	   Foster	   City,	   CA,	   USA).	   The	   three	  sequences	   used	   are	   shown	   in	   Table	   1.	   A	   scrambled	   siRNA	   without	   sequence	  homology	  to	  any	  known	  human	  gene	  was	  also	  obtained	  from	  Ambion	  and	  used	  as	  a	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negative	  control	  to	  prove	  that	  silencing	  of	  the	  gene	  of	  interest	  is	  due	  to	  specificity	  of	  siRNA	  and	  is	  not	  due	  to	  non-­‐specific	  effects.	  
Table	  1.	  Small	  interfering	  RNAs	  (siRNAs)	  sequences.	  
	   Transfection	  complexes	  were	  prepared	  in	  an	  Opti-­‐MEM	  serum	  free	  medium	  (Invitrogen)	   by	   mixing	   7	   µl	   of	   siPORT	   NeoFX	   transfection	   reagent	   (Applied	  Biosystems)	   and	   300	   nM	   of	   scramble/FGFR3	   siRNAs.	   Inmortalized	   human	  chondrocytes	  carrying	  the	  achondroplasia	  mutation	  were	  platted	  in	  a	  6	  well	  plate	  after	   the	   addition	   of	   transfection	   complexes.	   After	   72h,	   RNA	   and	   protein	   were	  isolated	  to	  analyze	  knockdown	  efficiency.	  
2.3.	  Reverse	  Transcriptase-­‐PCR	  Total	  RNA	  was	  extracted	  from	  the	  achondroplastic	  chondrocytes	  using	  the	  Nucleospin	  RNA/Protein	  Kit	   (Macherey-­‐Nagel,	  Düren,	  Germany)	  according	   to	   the	  instructions	   of	   the	   manufacturer	   and	   1	   µg	   was	   reverse	   transcribed	   using	  SuperScript	  III	  First-­‐Strand	  synthesis	  system	  Kit	  (Invitrogen).	  The	   FGFR3-­‐specific	   primers	   (forward	   5′-­‐	   TGCTGAATGCCTCCCACG	   -­‐3′	   and	  reverse	  5′-­‐	  CCAGGCTCCACTGCTGATG	  -­‐3′)	  that	  have	  been	  previously	  described	  (11,	  12)	   were	   employed	   for	   amplification	   of	   FGFR3.	   Glyceraldehyde-­‐3	   phosphate	  dehydrogenase	   (GAPDH)	   was	   used	   as	   an	   internal	   control	   and	   GAPDH-­‐specific	  primers	   (forward	   5′-­‐	   ACCACAGTCCATGCCATCAC	   -­‐3′	   and	   reverse	   5′-­‐	  TCCACCACCCTGTTGCTGTA	   -­‐3′)	   were	   purchased	   from	   Clontech	   (Clontech,	  Mountain	   View,	   CA,	   USA).	   Reactions	   were	   performed	   using	   TITANUM	   Taq	   DNA	  polymerase	  (Clontech).	  For	  FGFR3	  amplification,	  reactions	  conditions	  were	  94	  °C	  for	  3	  minutes,	  followed	  by	  35	  cycles	  at	  94	  °C	  for	  1	  minute,	  60	  °C	  for	  1	  minute,	  and	  72	   °C	   for	   10	   minutes.	   The	   thermal	   cycling	   conditions	   for	   GAPDH	   amplification	  were	  94	  °C	  for	  5	  minutes,	  followed	  by	  30	  cycles	  at	  94	  °C	  for	  45	  seconds,	  60	  °C	  for	  45	  seconds,	  72	  °C	  for	  2	  minutes	  and	  72	  °C	  for	  7	  minutes.	  PCR	   products	   were	   electrophoresed	   on	   1.5%	   agarose	   gel,	   stained	   by	  ethidium	  bromide	  and	  quantified	  using	  a	  Kodak	  GL	  200	  Imaging	  system	  and	  Kodak	  Molecular	  Imaging	  software	  (Kodak,	  Rochester,	  NY,	  USA).	  The	  values	  of	  the	  ratio	  of	  FGFR3	   to	  GAPDH	  were	   calculated	  and	  normalized	  by	   scramble	   control	  when	   the	  value	  of	  scramble	  control	  was	  defined	  as	  100%.	  
2.4.	  Western	  Blot	  Analysis	  Total	   protein	   from	   achondroplastic	   chondrocytes	   transfected	   with	   the	  siRNAs	  were	  isolated	  using	  the	  Nucleospin	  RNA/Protein	  Kit	  (Macherey-­‐Nagel)	  and	  protein	   concentration	   was	   determined	   by	   the	   Protein	   Quantification	   assay	  (Macherey-­‐Nagel).	  
siRNAs	   Sense	  (5´-­‐3´)	   Anti-­‐sense	  (5´-­‐3´)	  SEQ	  1	   CCGUAGCCGUGAAGAUGCUTT	   AGCAUCUUCACGGCUACGGTG	  SEQ	  2	   CCUGCGUCGUGGAGAACAATT	   UUGUUCUCCACGACGCAGGTG	  SEQ	  3	   AGGUGUACAGUGACGCACATT	   UGUGCGUCACUGUACACCUTG	  





15	   µg	   of	   protein	   from	   each	   sample	   were	   subjected	   to	   10%	   SDS-­‐polyacrilamide	  gels	  and	  were	  transferred	  to	  nitrocellulose	  membranes.	  Thereafter	  membranes	   were	   blocked	   and	   incubated	   overnight	   with	   anti-­‐FGFR3	   (1:100)	   or	  pERK1/2	   (1:1,000)	   (Santa	   Cruz	   Biotechnology,	   Santa	   Cruz,	   CA,	   USA).	   After	  washing,	   blots	   were	   incubated	   with	   peroxidase-­‐conjugated	   secondary	   antibody.	  Development	   was	   performed	   using	   ECL	   system	   (Amersham,	   Buckinghamshire,	  UK).	  To	   verify	   equal	   loading,	  membranes	  were	   stripped	   in	  62.5	  mM	  Tris-­‐HCl	  pH	  6.8,	   2%	   SDS	   and	   100	  mM	  2-­‐mercaptoethanol	   and	   re-­‐blotted	  with	   the	   antibodies	  GAPDH	   (1:2,500)	   (Abcam,	   Cambridge,	   UK)	   and	   ERK2	   (1:2,000)	   (Santa	   Cruz	  Biotechnology).	  Films	  were	  scanned	  and	  a	  densitometric	  analysis	  was	  performed	  using	  Kodak	  GL	  200	  Imaging	  system	  and	  Kodak	  Molecular	  Imaging	  software.	  The	  intensity	   of	   the	   bands	   quantified	   by	   densitometry	   was	   graphed.	   Data	   were	  normalized	  by	  FGFR3	  protein	   levels	  of	   the	  scramble	  control,	  defined	  as	  100%.	  In	  the	   case	   of	   ERK1/2	   phosphorylation,	   data	   were	   normalized	   by	   ERK1/2	  phosphorylation	   levels	   of	   the	   scramble	   control,	   defined	   as	   100%.	   All	   the	   data	  shown	  are	  representative	  of	  three	  independent	  experiments.	  
2.5.	  Statistical	  Analysis	  The	   differences	   between	   the	   mean	   values	   were	   analyzed	   with	   InStat3	  software	   (GraphPad	   Software,	   La	   Jolla,	   CA,	   USA)	   using	   ANOVA	   test;	   statistical	  significance	  was	  considered	  to	  be	  achieved	  at	  the	  P	  <	  0.05	  level.	  
 
3. RESULTS 
3.1.	  Silencing	  of	  FGFR3	  in	  human	  achondroplastic	  chondrocytes	  by	  siRNAs	  siRNAs	  were	  transfected	  into	  human	  achondroplastic	  chondrocytes	  and	  72	  h	  later	  the	  ability	  of	  the	  selected	  siRNA	  sequences	  to	  knockdown	  FGFR3	  mRNA	  and	  protein	  levels	  was	  analyzed	  by	  RT-­‐PCR	  and	  Western	  Blot,	  respectively	  (Figure	  1).	  Of	  the	  three	  siRNA	  sequences	  tested	  in	  achondroplastic	  chondrocytes,	  sequences	  1	  and	  2	  showed	  55%	  and	  75%	  knockdown	  of	  FGFR3	  mRNA	  expression,	  respectively,	  as	  compared	  to	  scramble	  control	  (Figure	  1A).	  siRNA	  sequence	  3	  was	  less	  effective	  at	  reducing	  FGFR3	  mRNA	  expression	  and	  only	  38%	  reduction	  was	  detected.	  Western	  blot	  analysis	  of	   cell	   culture	   lysates	   from	  these	  cells	   revealed	   that	  the	   amount	   of	   FGFR3	   protein	   also	   decreased	   (Figure	   1B).	   In	   particular,	  densitometry	  of	   immunoblots	   indicated	  that	  FGFR3	  protein	  was	  reduced	  by	  52%	  and	  61%	  with	  sequence	  1	  and	  2,	  respectively.	  Once	  more,	  the	  sequence	  3	  induced	  a	  lower	  decrease	  as	  compared	  to	  the	  scramble	  control	  (20%	  of	  reduction).	  
3.2.	  Effect	  of	  FGFR3	  knockdown	  on	  ERK1/2	  activation	  To	  investigate	  the	  impact	  of	  FGFR3	  silencing	  on	  downstream	  signalling,	  the	  phosphorylation	   status	   of	   ERK1/2	   was	   evaluated	   (Figure	   2).	   siRNA	   sequence	   2	  reduced	  ERK1/2	  phosphorylation	  by	  41%	  as	  compared	  to	  scramble	  control	  levels.	  Although	   to	   a	   lesser	   extent,	   siRNA	   sequence	   1	   also	   decreased	   the	   levels	   of	  phosphorylated	   ERK1/2	   (27%	   of	   reduction),	   whereas	   siRNA	   sequence	   3	   hardly	  modified	   the	   degree	   of	   phosphorylation	   of	   ERK1/2	  when	   compared	   to	   scramble	  control.	  	  





Figure	   1.	   FGFR3	   expression	   after	   siRNA	   transfection.	   siRNAs	   were	   introduced	   into	   human	  
achondroplastic	  chondrocytes	  and	  FGFR3	  mRNA	  (A)	  and	  FGFR3	  protein	  (B)	  were	  assessed	  72	  h	  later.	  *P	  
<	  0.05,	  **P	  <	  0.01.	  
	   	  
	  	  
Figure	   2.	   Effect	   of	   FGFR3	   knockdown	   on	   ERK1/2	   phosphorylation.	   Cell	   lysates	   of	   human	  
achondroplastic	   chondrocytes	   transfected	   with	   siRNAs	   were	   successively	   inmunoblotted	   with	   anti-­‐
pERK1/2	  and	  anti-­‐ERK2	  antibody	  to	  verify	  equal	  loading.	  *P	  <	  0.05.	  





4. DISCUSSION RNA	   interference	   is	   emerging	   as	   a	   strategy	   for	   the	   highly	   specific	  suppression	  of	  gene	  expression,	  both	  in	  vitro	  and	  in	  vivo.	  The	  present	  work	  shows	  the	  use	  of	  siRNA	  duplexes	  targeting	  FGFR3	  to	  knockdown	  the	  mRNA	  and	  protein	  expression	   levels	   of	   this	   receptor	   in	   immortalized	   human	   chondrocytes	   carrying	  the	  achondroplasia	  mutation	  (G380R).	  Our	  results	  are	  consistent	  with	  previous	  studies	  demonstrating	  that	  siRNAs	  targeting	  distinct	  mRNA	  sequences	  results	  in	  different	  silencing	  efficiency	  (11,	  13).	  A	   significant	   decrease	   of	   FGFR3	   mRNA	   and	   protein	   levels	   was	   observed	   after	  transient	  transfection	  with	  siRNA	  sequences	  1	  and	  2,	  while	  the	  siRNA	  sequence	  3	  did	  not	  induce	  FGFR3	  down-­‐regulation	  in	  the	  same	  extent.	  Activation	   of	   FGFR3	   results	   in	   trans-­‐autophosphorylation	   of	   juxtaposed	  intracellular	  kinase	  domains	  with	  subsequent	  recruitments	  of	  signalling	  molecules	  leading	   to	   phosphorylation	   and	   activation	   of	   different	   signalling	   pathways.	  Therefore,	  we	   determined	  whether	   these	   signalling	   pathways	  were	   also	   affected	  by	  FGFR3	  knockdown.	  In	  particular,	  we	  have	  analyzed	  one	  of	  the	  best	  known	  and	  characterized	   downstream	   signal	   transduction	   pathways	   coupled	   to	   FGFR3,	   the	  ERK	   mitogen	   activated	   protein	   kinase	   cascade.	   The	   sustained	   activation	   of	   this	  pathway	   is	   involved	   in	   the	   inhibitory	   effect	   of	   FGF	   signalling	   on	   chondrocyte	  proliferation	  and	  cartilage	  matrix	  production	  (3,	  5).	  FGFR3	  knockdown	  by	  siRNAs	  (siRNAs	   sequence	   1	   and	   2)	   attenuated	   the	   ERK1/2	   phosphorylation	   suggesting	  that	   the	   negative	   effects	   mediated	   by	   this	   pathway	   could	   be	   counteracted	   by	  siRNAs	  targeting	  FGFR3.	  RNA	   interference	   strategies	   have	   been	   previously	   described	   in	   different	  types	   of	   cancer	   cells	   that	   have	   activating	  mutations	   in	   FGFR3.	   In	   bladder	   cancer	  cells,	   knockdown	   of	   FGFR3	   by	   siRNAs	   lead	   to	   decrease	   proliferation,	   reduced	  clonogenicity	  and	  soft	  agar	  growth	  (14).	  Similarly,	  siRNA-­‐mediated	  knockdown	  of	  FGFR3	   inhibited	   anchorage-­‐independent	   growth	  of	   adrenal	   carcinoma	   cells	   (12).	  Inhibition	   of	   FGFR3	   expression	   by	   RNA	   interference	   has	   been	   also	   reported	   in	  multiple	   myeloma	   cells	   (11).	   On	   the	   other	   hand,	   regarding	   skull	   and	   skeletal	  growth	   disorders,	   RNA	   interference	   to	   knock-­‐down	   the	   expression	   of	   a	   mutant	  FGFR2	  has	  been	  used	  in	  Apert	  syndrome,	  a	  classic	  severe	  form	  of	  craniosynostosis	  (15).	  However,	  to	  our	  knowledge	  we	  have	  shown	  for	  the	  first	  time	  the	  use	  of	  RNA	  interference	  targeting	  FGFR3	  in	  human	  achondroplastic	  chondrocytes.	  Although	  several	  therapeutic	  approaches	  have	  emerged	  for	  achondroplasia	  treatment,	  the	  translation	  of	  these	  therapies	  into	  the	  clinic	  has	  not	  taken	  place.	  One	  of	  the	  main	  troubles	  for	  the	  success	  of	  new	  therapies	  is	  the	  delivery	  of	  compounds	  to	   growth	   plate	   chondrocytes	   of	   cartilage.	   The	   avascular	   nature	   of	   the	   cartilage	  tissue	  represents	  a	  challenge	  for	  drug	  delivery.	  Conjugation	  of	  siRNAs	  with	  small	  molecules	   that	   posses	   affinity	   for	   cartilage	   or	   chondrocytes	   could	   facilitate	   the	  target	   to	   growth	  plate	   chondrocytes	   of	   cartilage.	   In	   this	   sense,	   several	   strategies	  have	   been	   developed	   to	   promote	   cell/tissue-­‐specific	   siRNA	   delivery	   (16).	  Additionally,	   the	  dense	   extracellular	  matrix	   that	   surround	   chondrocytes	   form	  an	  important	   barrier	   for	   drug	   delivery.	   However,	   siRNAs	   are	   small	   enough	   that	  diffusion	  through	  extracellular	  matrix	  should	  not	  be	  an	  issue.	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5. CONCLUSION Our	   findings	   indicate	   that	   RNA	   interference	   targeting	   FGFR3	   could	   be	   a	  promising	   therapeutic	   option	   for	   achondroplasia	   in	   the	   future.	   Hopefully,	   new	  advances	   in	   delivery	   strategies	   to	   growth	   plate	   chondrocytes	   of	   cartilage	   will	  facilitate	  the	  development	  of	  siRNA-­‐based	  therapy.	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